A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
on May 24, 2019 at 4:36 am
Cisplatin yields significant efficacy and is generally used as a frontline therapy for non-small cell lung cancer (NSCLC ... migration of cisplatin-resistant NSCLC cells. Notably, co-treatment with ... […]
Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer
on May 24, 2019 at 2:20 am
Tunneling nanotubes (TNTs) are actin-based membranous structures bridging distant cells for intercellular communication. We define roles for TNTs in stress adaptation and treatment resistance in ... […]
Texas teacher diagnosed with cancer while undergoing treatment for car crash
on May 23, 2019 at 6:05 pm
David Smith was being treated after a single-vehicle crash when doctors found masses in his brain, chest, and kidney. ... […]
"Varian Medical Systems (VAR) To Discuss Agreement To Acquire Cancer Treatment Services International - Slideshow "
on May 23, 2019 at 11:50 am
The following slide deck was published by Varian Medical Systems, Inc. in conjunction with this event. 112 Click to enlarge Notes: ... […]
Steps to Sustainable Cancer Treatment
on May 23, 2019 at 9:50 am
Senior representatives from four African IAEA Member States - Chad, Eswatini, Liberia and Sierra Leone - came to Vienna last week to develop planning and funding proposals for the establishment of the ... […]
3 Cancer Treatment Stocks to Buy Right Now
on May 23, 2019 at 5:15 am
There's good news in the fight against cancer. While the disease continues to affect way too many people across the world, innovative companies are making progress in more effective ways to diagnose ... […]
BBC newsreader Jane Hill reveals breast cancer treatment
on May 23, 2019 at 4:07 am
BBC newsreader Jane Hill has revealed she has been treated for breast cancer. The journalist has returned to work after a six-month hiatus. "Overwhelmed by so many lovely back-to-work messages," she ... […]
'Dance Moms' Star Abby Lee Miller Says She's Officially Cancer Free, After More Than A Year Of Treatment
on May 22, 2019 at 9:03 pm
Abby Lee Miller announced she is cancer free in a new interview. After being diagnosed with Burkitt lymphoma in April 2018, Abby has undergone 10 rounds of chemo and multiple emergency surgeries. Abby ... […]
Meghan McCain says Ben Carson should be developing brain cancer treatment, not working at HUD
on May 22, 2019 at 3:15 pm
"The View" co-host Meghan McCain Meghan Marguerite McCain Meghan McCain says Ben Carson should be developing brain cancer treatment, not working at HUD Stormy Daniels praises Meghan McCain for ... […]
via Bing News